ABSTRACT
The objective was to evaluate the determination of biomarkers of air quality during a mass gathering event at a convention center using a novel air sampling device, AirAnswers®. This sampler has previously only been used in smaller locations. Here it was run at five crowded locations within the exhibit area for the four days duration of a trade show. The AirAnswers® device uses electro-kinetic flow to sample air at high rates and capture bio-aerosols on grounded electrodes in assayable form. Cartridges were removed from the devices and immediately conveyed to the Inspirotec facility in North Chicago, where assays were performed.
Biomarkers determined were for allergens and molds previously described for this system. Testing for a new marker, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was also included. The method was validated by determination of capture efficiency with reference to an impinger sampler in a Class III controlled environment chamber. Average capture efficiency for triplicate runs was 14%. One SARS-CoV-2 positive sample as found at the registration area, which was physically separate from the main exhibit area.
Cat allergen Fel d 1was found in four of the locations, dog allergen Can f 1 at two. The airborne biomarker of mold proliferation, (1→3)-β-D-Glucan, was above the assay range in all locations. The widespread presence of this mold marker could be accounted for by signs of water leakage. A generic 18S RNA marker for mold was developed and similarly showed the presence of mold in all locations, as was a genus marker for penicillium. A species marker for Cladosporium cladosporioides was in two locations. Species markers for Eurotium amstelodami and Trichoderma viride were each in a single location.
The main findings were of the widespread presence of mold markers, and the sporadic appearance of SARS-CoV-2. Masking was recommended but not enforced.
Competing Interest Statement
JG, OA, RR, KH, CS, HR and SK are employees or contractors of Inspirotec Inc receiving remuneration, stocks or options and therefore have an interest in the commercial success of Inspirotec. RT, KS, BK and JW are employees of MRI-Global, performers of independent research with no interest in the outcome of the work. GM is an employee of the Global Biorisk Advisory Council, which performs accreditations and has no financial interest in the outcome of this work.
Funding Statement
This study was funded by Inspirotec Inc
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript